Mark H. Wilcox, MD

PROFESSOR OF MEDICAL MICROBIOLOGY
LEEDS TEACHING HOSPITALS & UNIVERSITY OF LEEDS

Disclosure: Abbott (Grant/Research Support)Actelion (Consultant, Grant/Research Support)Alere (Consultant, Grant/Research Support)Astellas (Consultant, Grant/Research Support)Astra-Zeneca (Consultant)Basilea (Consultant)Bayer (Consultant)Biomerieux (Grant/Research Support)Cerexa (Grant/Research Support)Cubist (Consultant, Grant/Research Support)Da Volterra (Grant/Research Support)Durata (Consultant, Grant/Research Support)European Tissue Symposium (Consultant, Grant/Research Support)J&J (Consultant)Merck (Consultant, Grant/Research Support)Nabriva (Consultant)Novacta (Consultant)Novartis (Consultant)Optimer (Consultant)Pfizer (Consultant, Speaker's Bureau)Qiagen (Grant/Research Support)Roche (Consultant)Sanofi-Pasteur (Consultant, Grant/Research Support)Seres (Consultant)Summit (Grant/Research Support)The Medicines Company (Grant/Research Support)

Presentation(s):

• LB-5 - DAV132 Protects Intestinal Microbiota of Patients Treated with Quinolones, a European Phase II Randomized Controlled Trial (SHIELD)

  Saturday, October 24, 2020
  10:30am – 10:40am EDT